TETRABENAZINE - Generic Drug Details

What are the generic drug sources for tetrabenazine and what is the scope of patent protection?

Tetrabenazine is the generic ingredient in two branded drugs marketed by Actavis Labs Fl Inc, Adaptis, Ajanta Pharma Ltd, Apotex, Bionpharma, Chartwell Rx, Dr Reddys, Hetero Labs Ltd V, Hikma, Mylan, Sun Pharm, and Bausch, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are twelve drug master file entries for tetrabenazine. Twelve suppliers are listed for this compound.

Summary for TETRABENAZINE

US Patents:	0
Tradenames:	2
Applicants:	12
NDAs:	12
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	115
Clinical Trials:	14
Patent Applications:	4,632
Drug Prices:	Drug price trends for TETRABENAZINE
What excipients (inactive ingredients) are in TETRABENAZINE?	TETRABENAZINE excipients list
DailyMed Link:	TETRABENAZINE at DailyMed

See drug prices for TETRABENAZINE

Recent Clinical Trials for TETRABENAZINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Virginia Commonwealth University	PHASE2
H. Lundbeck A/S	Phase 4
William Ondo, MD	Phase 4

See all TETRABENAZINE clinical trials

Pharmacology for TETRABENAZINE

Drug Class	Vesicular Monoamine Transporter 2 Inhibitor
Mechanism of Action	Vesicular Monoamine Transporter 2 Inhibitors

Medical Subject Heading (MeSH) Categories for TETRABENAZINE

Adrenergic Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for TETRABENAZINE

N07XX	Other nervous system drugs
N07X	OTHER NERVOUS SYSTEM DRUGS
N07	OTHER NERVOUS SYSTEM DRUGS
N	Nervous system

US Patents and Regulatory Information for TETRABENAZINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	TETRABENAZINE	tetrabenazine	TABLET;ORAL	206129-002	Aug 17, 2015		DISCN	No	No
Hikma	TETRABENAZINE	tetrabenazine	TABLET;ORAL	209739-002	Apr 8, 2019		DISCN	No	No
Bionpharma	TETRABENAZINE	tetrabenazine	TABLET;ORAL	208826-001	Dec 18, 2017	AB	RX	No	No
Actavis Labs Fl Inc	TETRABENAZINE	tetrabenazine	TABLET;ORAL	206686-001	Jul 7, 2017	AB	RX	No	No
Dr Reddys	TETRABENAZINE	tetrabenazine	TABLET;ORAL	209284-002	Jan 8, 2018	AB	RX	No	No

Market Dynamics and Financial Trajectory for Tetrabenazine

Last updated: February 13, 2026

Tetrabenazine is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for managing hyperkinetic movement disorders, notably Huntington's disease chorea. The drug’s market presence hinges on its efficacy, regulatory status, competition, and the evolving landscape of neuropsychiatric treatments.

Market Size and Growth Drivers

The global Huntington’s disease (HD) treatment market, of which tetrabenazine accounts for a significant segment, was valued at approximately $480 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8% through 2030[1].

Key drivers include:

• Increasing prevalence of HD, estimated at 3-5 cases per 100,000 globally[2].
• Growing awareness and diagnosis rates.
• Regulatory approvals extending indications for tetrabenazine beyond HD.

Regulatory and Patent Landscape

Tetrabenazine was approved in 2008 under the brand name Xenazine (Valeant Pharmaceuticals). Its patent protection expired in 2017, prompting generic manufacturers to introduce lower-cost alternatives, thus increasing market access but reducing branded sales margins[3].

Recent regulatory actions include:

• Approval of deutetrabenazine (Austedo) in 2017, offering a more selective and better-tolerated alternative for HD and other disorders.
• Extended indications for HD chorea, dystonia, and tardive dyskinesia.

The patent expiration led to a revenue decline for branded tetrabenazine, but it remains in use due to its established efficacy.

Competitive Environment

The competitive landscape includes:

Player	Product	Market Share (2022)	Notes
Teva Pharmaceuticals	generic tetrabenazine	60%	Dominates due to early market entry
Neurocrine Biosciences	Austedo (deutetrabenazine)	30%	Newer, better-tolerated option
Others	Various generics	10%	Price-based competition

Generic tetrabenazine remains a low-cost alternative, pressuring prices of branded formulations.

Pricing and Revenue Trajectory

Post-patent expiration, the price of tetrabenazine declined by an estimated 50-60%. Current annual revenues for branded tetrabenazine tip below $50 million globally, driven by off-label use and generics[4].

In regions with less generic penetration, sales are potentially higher but generally offset by pricing pressure. The adoption of newer agents like deutetrabenazine affects the market share of traditional tetrabenazine.

Regulatory and Clinical Development Impact

Research into extended indications, such as for Tourette syndrome or other hyperkinetic movement disorders, could expand market size. Clinical trials for improved formulations or combination therapies remain ongoing.

Future Outlook and Risks

The market future depends on:

• Success in expanding FDA or EMA indications.
• Development of better-tolerated alternatives.
• Price competition from generics.
• Entry of biosimilars or novel therapeutic classes addressing similar conditions.

Risks include patent litigation, regulatory delays, and market saturation.

---

Key Takeaways

• Tetrabenazine's core market has diminished due to patent expiration and generics, with revenues likely under $50 million annually.
• Growth potential exists through expanded approved uses but is limited by competition and pricing pressures.
• The emergence of alternative agents like deutetrabenazine has shifted market dynamics toward newer therapies.
• Future revenues depend on regulatory approval of new indications and formulations.

---

Frequently Asked Questions

1. What is the primary use of tetrabenazine?
   It treats chorea associated with Huntington's disease and selected hyperkinetic movement disorders.

2. Why did tetrabenazine’s market decline after 2017?
   Patent expiration and generic entry reduced branded sales and prices.

3. How does deutetrabenazine compare to tetrabenazine?
   It offers improved tolerability, less frequent dosing, but generally commands higher prices and targets similar indications.

4. Are there ongoing efforts to improve tetrabenazine?
   Research focuses on better formulations and expanding indications, but no major new patents are imminent.

5. What is the outlook for tetrabenazine’s market?
   The market will likely decline due to generics but may stabilize if new indications or formulations are approved.

---

References

[1] Markets and Markets, "Neurodegenerative Disease Treatment Market," 2022.

[2] HD Census data, 2023.

[3] FDA. "Tetrabenazine: Patent and Market Status," 2017.

[4] IMS Health, "Pharmaceutical Sales Data," 2022.